This white paper explores flexible, data-driven strategies that help streamline biologics development, mitigate risks, and accelerate timelines—especially when transitioning from underperforming systems or navigating fast-track regulatory pathways.
What you’ll learn
- How Lonza’s modular technology transfer approach supports both proprietary and in-house cell lines across diverse expression systems.
- Case studies showcasing productivity gains of up to 250% and successful transitions to cGMP scale.
- Solutions to primary recovery challenges and enhanced process robustness for complex molecules, including non-CHO cell lines.
- Strategic process design and bioreactor optimization to ensure scalability, consistency, and regulatory compliance.
Ready to overcome development hurdles and scale with confidence? Complete the form to download the full white paper and unlock actionable insights for your next biologics milestone.